Helmut Albrecht

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

François Raffi, Hans Jaeger, Eugenia Quirós-Roldán et al. · The Lancet Infectious Diseases · 2013 · 372 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

Loss of CD127 Expression Defines an Expansion of Effector CD8+ T Cells in HIV-Infected Individuals

Mirko Paiardini, Barbara Cervasi, Helmut Albrecht et al. · The Journal of Immunology · 2005 · 229 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Bryostatin Modulates Latent HIV-1 Infection via PKC and AMPK Signaling but Inhibits Acute Infection in a Receptor Independent Manner

Rajeev Mehla, Shalmali Bivalkar-Mehla, Ruonan Zhang et al. · PLoS ONE · 2010 · 225 citations · Full text

Life Sciences, Immunology, Pharmacology +17

Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy

Helmut Albrecht, Christian Hoffmann, Olaf Degen et al. · AIDS · 1998 · 151 citations

Medicine, Infectious Diseases, Pharmacology +12

Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial

Hans‐Jürgen Stellbrink, José Ramón Arribas, Jeffrey L. Stephens et al. · The Lancet HIV · 2019 · 143 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16